XERIS BIOPHARMA HOLDINGS, INC. Restructuring Charges
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Restructuring Charges of $275.00 thousand for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2021-11-10
- 2021-09-30: Restructuring Charges 9 month $275.00K.
| Period end | Restructuring Charges 9 month |
|---|---|
| 2021-09-30 | $275.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |